Skip to content
Brand AI

Tagrisso

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2020

    FDA approves Tagrisso for adjuvant NSCLC therapy

    The FDA approved osimertinib (Tagrisso, AstraZeneca) as adjuvant therapy for patients with non-small cell lung cancer with EGFR mutations. The new indication covers patients with specified EGFR mutations after tumor resection.

    Source